OBJECTIVES: To assess the effects of treatments for basal cell carcinoma. METHODS: Systematic review of randomised controlled trials. MAIN OUTCOME MEASURE: Recurrence of basal cell carcinoma at three years or beyond, assessed clinically. STUDIES REVIEWED: Randomised controlled trials of interventions for histologically confirmed basal cell carcinoma (published and unpublished material; no language restrictions). RESULTS: 25 studies were identified, covering seven therapeutic categories. Only one study of surgical excision versus radiotherapy contained primary outcome data, which showed significantly more persistent tumours and recurrences in the radiotherapy group compared with surgery (odds ratio 0.09, 95% confidence interval 0.01 to 0.67). One study compared cryotherapy with surgery, with inconclusive results at one year. In a comparison of radiotherapy with cryotherapy, significantly more recurrences occurred at one year in the cryotherapy group. Preliminary studies suggest a short term success rate of 87-88% for imiquimod cream in the treatment of superficial basal cell carcinoma, although this cream has not been compared with surgery. No consistent evidence was found for the other treatment modalities. CONCLUSIONS: Little good quality research has been done on the treatments used for the most common cancer in humans. Most trials have included only people with basal cell carcinoma occurring at low risk sites. Only one trial measured recurrence at four years; recurrence rates at one year should be interpreted with caution. Surgery and radiotherapy seem to be the most effective treatments; surgery showed the lowest failure rates. Other treatments might have some use but need to be compared with surgery.
OBJECTIVES: To assess the effects of treatments for basal cell carcinoma. METHODS: Systematic review of randomised controlled trials. MAIN OUTCOME MEASURE: Recurrence of basal cell carcinoma at three years or beyond, assessed clinically. STUDIES REVIEWED: Randomised controlled trials of interventions for histologically confirmed basal cell carcinoma (published and unpublished material; no language restrictions). RESULTS: 25 studies were identified, covering seven therapeutic categories. Only one study of surgical excision versus radiotherapy contained primary outcome data, which showed significantly more persistent tumours and recurrences in the radiotherapy group compared with surgery (odds ratio 0.09, 95% confidence interval 0.01 to 0.67). One study compared cryotherapy with surgery, with inconclusive results at one year. In a comparison of radiotherapy with cryotherapy, significantly more recurrences occurred at one year in the cryotherapy group. Preliminary studies suggest a short term success rate of 87-88% for imiquimod cream in the treatment of superficial basal cell carcinoma, although this cream has not been compared with surgery. No consistent evidence was found for the other treatment modalities. CONCLUSIONS: Little good quality research has been done on the treatments used for the most common cancer in humans. Most trials have included only people with basal cell carcinoma occurring at low risk sites. Only one trial measured recurrence at four years; recurrence rates at one year should be interpreted with caution. Surgery and radiotherapy seem to be the most effective treatments; surgery showed the lowest failure rates. Other treatments might have some use but need to be compared with surgery.
Authors: I Wang; N Bendsoe; C A Klinteberg; A M Enejder; S Andersson-Engels; S Svanberg; K Svanberg Journal: Br J Dermatol Date: 2001-04 Impact factor: 9.302
Authors: A M Enejder; C af Klinteberg; I Wang; S Andersson-Engels; N Bendsoe; S Svanberg; K Svanberg Journal: Acta Derm Venereol Date: 2000 Jan-Feb Impact factor: 4.437
Authors: A M Soler; E Angell-Petersen; T Warloe; J Tausjø; H B Steen; J Moan; K E Giercksky Journal: Photochem Photobiol Date: 2000-06 Impact factor: 3.421
Authors: J Y Petit; M F Avril; A Margulis; D Chassagne; A Gerbaulet; P Duvillard; A Auperin; M Rietjens Journal: Plast Reconstr Surg Date: 2000-06 Impact factor: 4.730
Authors: John K Geisse; Phoebe Rich; Amit Pandya; Kenneth Gross; Kara Andres; Angie Ginkel; Mary Owens Journal: J Am Acad Dermatol Date: 2002-09 Impact factor: 11.527
Authors: Mary-Margaret Chren; Jeanette S Torres; Sarah E Stuart; Daniel Bertenthal; Remedios J Labrador; W John Boscardin Journal: Arch Dermatol Date: 2011-05
Authors: Eric M Bachelder; Tristan T Beaudette; Kyle E Broaders; Jean M J Fréchet; Mark T Albrecht; Alfred J Mateczun; Kristy M Ainslie; John T Pesce; Andrea M Keane-Myers Journal: Mol Pharm Date: 2010-06-07 Impact factor: 4.939
Authors: John Paoli; Johan Dahlén Gyllencreutz; Julia Fougelberg; Eva Johansson Backman; Maja Modin; Sam Polesie; Oscar Zaar Journal: Dermatol Pract Concept Date: 2019-04-30